ANGPTL7在眼压与青光眼中的作用
研究通过Angptl7基因敲除小鼠、人小梁网细胞、灌注人供体眼及兔眼模型,探讨ANGPTL7在眼压稳态中的作用。发现ANGPTL7增多可增加房水流出阻力与眼压,而中和ANGPTL7抗体可改善流出易度并降低兔眼压持续21天,提示其作为青光眼治疗靶点的潜力。
要点
- Angptl7敲除小鼠眼压显著升高,但流出易度与流出组织形态与野生型无差异。
- 地塞米松处理后野生型小鼠眼压升高,而Angptl7敲除小鼠眼压未升高。
- ANGPTL7阻断抗体可增加人眼流出易度,兔眼单次注射后眼压降低持续21天。
核心结论
- 多种模型证实过量ANGPTL7增加流出阻力与眼压,中和ANGPTL7在初始及类固醇诱导的高眼压眼中均有益处,作者据此提出开发靶向ANGPTL7的青光眼治疗药物。
研究设计与样本
- 研究采用Angptl7敲除小鼠(含地塞米松处理与否)、人小梁网细胞条件培养基、灌注人供体眼、人房水样本、三维培养流出细胞及兔眼玻璃体腔注射模型。
主要发现
- Angptl7敲除小鼠眼压显著升高,但流出易度与流出组织形态与同窝对照无差异。
- 地塞米松处理后野生型小鼠眼压升高,而Angptl7敲除小鼠眼压未升高。
- 接受类固醇治疗的患者房水中ANGPTL7升高,与青光眼状态无关。
- 三维培养中重组ANGPTL7降低水力传导率,而ANGPTL7阻断抗体增加水力传导率。
- 人供体眼体外经ANGPTL7阻断抗体处理后流出易度增加,兔眼单次注射阻断抗体后眼压降低持续21天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Loss-of-function variants in the ANGPTL7 gene are associated with protection from glaucoma and reduced intraocular pressure (IOP). We investigated the role of ANGPTL7 in IOP homeostasis and its potential as a target for glaucoma therapeutics. METHODS: IOP, outflow facility, and outflow tissue morphology of Angptl7 knockout (KO) mice were assessed with and without dexamethasone (Dex). ANGPTL7 was quantified in conditioned media from human trabecular meshwork cells in response to Dex, in effluent from perfused human donor eyes, and in aqueous humor from human patients treated with steroids. Antibodies to ANGPTL7 were generated and tested in three-dimensional (3D) culture of outflow cells and perfused human donor eyes. Rabbits were injected intravitreally with a neutralizing antibody targeting ANGPTL7, and IOP was measured. RESULTS: IOP was significantly elevated, but outflow facility and outflow tissue morphology were not different between Angptl7 KO mice and littermates. When challenged with Dex, IOP increased in wild-type but not Angptl7 KO mice. In human samples, increased ANGPTL7 was seen in the aqueous humor of patients treated with steroids, regardless of glaucoma status. Using 3D culture, recombinant ANGPTL7 decreased, and ANGPTL7-blocking antibodies increased hydraulic conductivity. Significantly, outflow facility increased in human eyes treated ex vivo with ANGPTL7-blocking antibodies, and IOP decreased for 21 days in rabbits after a single injection of blocking antibodies. CONCLUSIONS: Using multiple models, we have demonstrated that excess ANGPTL7 increases outflow resistance and IOP and that neutralizing ANGPTL7 has beneficial effects in both naïve and steroid-induced hypertensive eyes, thus motivating the development of ANGPTL7-targeting therapeutics for the treatment of glaucoma.
引用
- Brown SF, Nguyen H, Mzyk P, et al. ANGPTL7 and Its Role in IOP and Glaucoma. Invest Ophthalmol Vis Sci. 2024. PMID: 38497513. doi:10.1167/iovs.65.3.22
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。